WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

The company has already kicked off an open-label Phase I trial of ABX1100 in Canada following positive results from a study of healthy volunteers.

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

In SNALPs, the backbone-modified siRNA is encapsulated within a closed shell of a cationic-zwitterionic lipid bilayer, furnished with an outer PEG shield (Figure 2A). The lipid bilayer contains a ...

Sirna kakuu galuu Pirezidaant Tiraamp Wiixata darbe gaggeeffame irratti paastaroonni Afrikaa lama argamanii turan. Dawwaannaan Paastar Wiiliyaam Kumuuyi fi Paastar Naatinaa'el Baasey kun walitti ...

Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo Programs to focus on silencing hard-to-drug targets of high therapeutic ...

Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile ...

Dicer Enzymes. In a collaborative study with the David Bartel lab (MIT), we demonstrated that budding yeast Dicers initiate processing in the interior and work outwards in contrast to canonical Dicers ...

证券之星消息，根据天眼查APP数据显示凯莱英（002821）新获得一项发明专利授权，专利名为“抑制FXI基因表达的siRNA的制备方法”，专利申请号为CN202410921752.5，授权日为2025年1月28日。